KLS:7148

Duopharma Biotech Berhad · KLS · Healthcare · MYR · FY for 2025

Figures on this page computed 2026-11-08 12:26 UTC

Last close

n/aMYR

Market data

12.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
9.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
9.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
3.1%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Five bars, one line

lens 7 of 9

1.50x

1.54x

18.60x

1.43x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.50x
Its own average over 10 years, 621.2M.
Profit1.54x
Its own average over 10 years, 56.9M.
Free cash flow18.60x
Its own average over 10 years, 4.6M.
Debt1.43x
Its own average over 10 years, 344.7M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 18.60 times.

Sales is 1.50 times its own 10-year average; Profit is 1.54 times its own 10-year average; Free cash flow is 18.60 times its own 10-year average; Debt is 1.43 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average1.50
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Profit against its own 10-year average1.54
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Free cash flow against its own 10-year average18.60
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Debt against its own 10-year average1.43
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
MYR